Stock image for illustration purposes only - book cover, edition or condition may vary.
Glycogen Synthase Kinase-3 (GSK-3) and Its Inhibitors
Martinez
€ 187.64
FREE Delivery in Ireland
Description for Glycogen Synthase Kinase-3 (GSK-3) and Its Inhibitors
Hardcover. GSK-3 is a promising drug target that has been extensively tested, and shown great potential for treatment of diseases that have no current effective treatment - like Alzheimer's, bipolar disorder, and cancer. Editor(s): Martinez, Ana; Castro, Ana; Medina, Miguel. Series Editor(s): Wang, Binghe. Series: Wiley Series in Drug Discovery and Development. Num Pages: 346 pages, Illustrations (some col.). BIC Classification: PNN; PS. Category: (P) Professional & Vocational. Dimension: 235 x 162 x 24. Weight in Grams: 680.
Many researchers believe that GSK-3 and its inhibitors could lead to effective treatments for neurogenerative disorders, type II diabetes, depression and bipolar disorder, and some forms of cancer. This book provides a thorough introduction to GSK-3, presents up-to-date information, and mentions the birth of several chemical families of GSK-3 inhibitors with varying selectivity. It’s a great reference for researchers in drug design and development.
Many researchers believe that GSK-3 and its inhibitors could lead to effective treatments for neurogenerative disorders, type II diabetes, depression and bipolar disorder, and some forms of cancer. This book provides a thorough introduction to GSK-3, presents up-to-date information, and mentions the birth of several chemical families of GSK-3 inhibitors with varying selectivity. It’s a great reference for researchers in drug design and development.
Product Details
Format
Hardback
Publication date
2006
Publisher
John Wiley & Sons Inc United States
Number of pages
346
Condition
New
Series
Wiley Series in Drug Discovery and Development
Number of Pages
392
Place of Publication
, United States
ISBN
9780471770015
SKU
V9780471770015
Shipping Time
Usually ships in 15 to 20 working days
Ref
99-15
About Martinez
ANA MARTINEZ is the Research and Development Director for NeuroPharma. She has been and still is an active researcher in the design and synthesis of GSK-3 inhibitors. ANA CASTRO is the Medicinal Chemistry Director of NeuroPharma. She was formerly a tenured scientist at the Medicinal Chemistry Institute. MIGUEL MEDINA is the Drug Discovery Director at NeuroPharma. He was formerly an instructor at the Brigham and Women's Hospital and the Harvard Medical School.
Reviews for Glycogen Synthase Kinase-3 (GSK-3) and Its Inhibitors